Research Square · Aug 20, 2026

CIP2A promotes osteoclastogenesis and postmenopausal bone loss by activating a novel HMGA1–c-Myc–PI3K/AKT axis

By Zhu M, He J, Li J et al.

Background Osteoclast-mediated bone resorption drives osteoporosis, a prevalent skeletal disorder with significant clinical and socioeconomic burden, yet the upstream molecular mechanisms controlling osteoclast differentiation remain incompletely defined. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a known oncogenic regulator, but its role in bone metabolism and osteoclast biology has not been explored. Methods We used RANKL-induced mouse bone marrow macrophages (BMMs) to model osteoclast differentiation in vitro, with adenoviral-mediated gain- or loss-of-function of CIP2A. Mechanistic investigations included immunoprecipitation-mass spectrometry (IP-MS), co-immunoprecipitation (co-IP), ubiquitination assays, cycloheximide (CHX) chase analysis, RNA sequencing (RNA-seq), and chromatin immunoprecipitation sequencing (ChIP-seq). For translational assessment, in vivo, we employed an ovariectomy (OVX)-induced osteoporosis mouse model with systemic adeno-associated virus (AAV)-mediated gene manipulation as well as pharmacological inhibition using the CIP2A small-molecule inhibitor TD52. Results CIP2A expression was dynamically upregulated during RANKL-induced osteoclastogenesis. CIP2A promoted osteoclast formation, actin ring assembly, and bone resorptive activity in vitro, without affecting osteoblast differentiation. Mechanistically, CIP2A acted as a molecular scaffold that recruited the deubiquitinase OTUD4 to stabilize high mobility group A1 (HMGA1) by preventing its ubiquitination and proteasomal degradation. Stabilized HMGA1 translocated to the nucleus. Integrated multi-omics analyses (RNA-seq and HMGA1 ChIP-seq) identified c-Myc as a direct transcriptional target of HMGA1, which bound distal regulatory elements to enhance c-Myc transcription. Functional experiments further revealed that c-Myc formed a positive feedback loop with the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway, sustaining osteoclast activity. In OVX mice, c-Myc overexpression or AKT activation partially rescued the bone loss induced by CIP2A knockdown. Importantly, pharmacological inhibition of CIP2A with TD52 suppressed osteoclast differentiation and bone resorption both in vitro and in vivo, without causing major organ toxicity or affecting osteoblast function. Conclusions Our findings identify a novel CIP2A–OTUD4–HMGA1–c-Myc–PI3K/AKT regulatory axis that drives pathological osteoclastogenesis and bone loss. CIP2A represents a promising druggable target for osteoporosis and related osteolytic diseases. As a potential first-in-class CIP2A inhibitor, TD52 merits further preclinical development for the treatment of postmenopausal osteoporosis.

doi.org/10.21203/rs.3.rs-9848947/v1Open accessMechanisms

AgingResearch.News